scholarly journals Immune rejection of human dystrophin following intramuscular injections of naked DNA in mdx mice

Gene Therapy ◽  
2000 ◽  
Vol 7 (17) ◽  
pp. 1447-1457 ◽  
Author(s):  
S Braun ◽  
C Thioudellet ◽  
P Rodriguez ◽  
D Ali-Hadji ◽  
F Perraud ◽  
...  
2015 ◽  
Vol 20 (3) ◽  
Author(s):  
Rongqing Pang ◽  
Xiangqing Zhu ◽  
Jia Geng ◽  
Yongyun Zhang ◽  
Qiang Wang ◽  
...  

AbstractMultipotent stem cells have potential therapeutic roles in the treatment of Duchenne muscular dystrophy (DMD). However, the limited access to stem cell sources restricts their clinical application. To address this issue, we established a simple in vitro epigenetic reprogramming technique in which skin fibroblasts are induced to dedifferentiate into multipotent cells. In this study, human fibroblasts were isolated from circumcised adult foreskin and were reprogrammed by co-culture for 72 h with fish oocyte extract (FOE) in serum-free medium. The cells were then observed and analyzed by immunofluorescence staining, flow cytometry and in vitro differentiation assays. Then FOE-treated human fibroblasts were transplanted by tail vein injection into irradiated mdx mice, an animal model of DMD. Two months after injection, the therapeutic effects of FOE-treated fibroblasts on mdx skeletal muscle were evaluated by serum creatine kinase (CK) activity measurements and by immunostaining and RT-PCR of human dystrophin expression. The results indicated that the reprogrammed fibroblasts expressed higher levels of the pluripotent antigen markers SSEA-4, Nanog and Oct-4, and were able to differentiate in vitro into adipogenic cells, osteoblastic cells, and myotube-like cells. Tail vein injection of FOE-treated fibroblasts into irradiated mdx mice slightly reduced serum CK activity and the percentage of centrally nucleated myofibers two months after cell transplantation. Furthermore, we confirmed human dystrophin protein and mRNA expression in mdx mouse skeletal muscle. These data demonstrated that FOE-treated fibroblasts were multipotent and could integrate into mdx mouse myofibers through the vasculature.


2006 ◽  
Vol 13 ◽  
pp. S16
Author(s):  
Bing Wang ◽  
Juan Li ◽  
Chunlian Chen ◽  
Xiancheng Jiang ◽  
Terry O'Day ◽  
...  

1993 ◽  
Vol 2 (2) ◽  
pp. 113-118 ◽  
Author(s):  
Johnny Huard ◽  
Geneviève Tremblay ◽  
Steve Verreault ◽  
Claude Labrecque ◽  
Jacques P. Tremblay

Human myoblasts were transplanted in nude mice. The efficacy of these transplantations was analyzed using a monoclonal antibody (NCLDys3) specific for human dystrophin. This antibody did not reveal any dystrophin in nude mice that did not receive a human myoblast transplantation. However, about 30 days after a human myoblast transplantation, dystrophin-positive muscle fibers were observed. They were not abundant, and were present either in small clusters or isolated. This technique follows the fate of myoblast transplantation in animals that already have dystrophin, and distinguishes between new dystrophin-positive fibers due to the transplantation and the revertant fibers in mdx mice. Moreover, this technique does not require any labelling of the myoblasts before transplantation. It can also be used to detect dystrophin produced following the fusion of myoblasts transfected with the human dystrophin gene.


2016 ◽  
Vol 24 ◽  
pp. S226
Author(s):  
William-Édouard Gravel ◽  
Dominique L. Oulette ◽  
Chantale Maltais ◽  
Catherine Gérard ◽  
Hongmei L. Li ◽  
...  

2007 ◽  
Vol 18 (5) ◽  
pp. 1586-1594 ◽  
Author(s):  
Chang-Hao Cui ◽  
Taro Uyama ◽  
Kenji Miyado ◽  
Masanori Terai ◽  
Satoru Kyo ◽  
...  

Duchenne muscular dystrophy (DMD), the most common lethal genetic disorder in children, is an X-linked recessive muscle disease characterized by the absence of dystrophin at the sarcolemma of muscle fibers. We examined a putative endometrial progenitor obtained from endometrial tissue samples to determine whether these cells repair muscular degeneration in a murine mdx model of DMD. Implanted cells conferred human dystrophin in degenerated muscle of immunodeficient mdx mice. We then examined menstrual blood–derived cells to determine whether primarily cultured nontransformed cells also repair dystrophied muscle. In vivo transfer of menstrual blood–derived cells into dystrophic muscles of immunodeficient mdx mice restored sarcolemmal expression of dystrophin. Labeling of implanted cells with enhanced green fluorescent protein and differential staining of human and murine nuclei suggest that human dystrophin expression is due to cell fusion between host myocytes and implanted cells. In vitro analysis revealed that endometrial progenitor cells and menstrual blood–derived cells can efficiently transdifferentiate into myoblasts/myocytes, fuse to C2C12 murine myoblasts by in vitro coculturing, and start to express dystrophin after fusion. These results demonstrate that the endometrial progenitor cells and menstrual blood–derived cells can transfer dystrophin into dystrophied myocytes through cell fusion and transdifferentiation in vitro and in vivo.


Nature ◽  
1991 ◽  
Vol 352 (6338) ◽  
pp. 815-818 ◽  
Author(s):  
Gyula Acsadi ◽  
George Dickson ◽  
Donald R. Love ◽  
Agnes Jani ◽  
Frank S. Walsh ◽  
...  

Gene Therapy ◽  
2004 ◽  
Vol 11 (11) ◽  
pp. 884-893 ◽  
Author(s):  
A Ferrer ◽  
H Foster ◽  
K E Wells ◽  
G Dickson ◽  
D J Wells

1992 ◽  
Vol 32 (5) ◽  
pp. 621-621
Author(s):  
Gyula Acsádi ◽  
Ágnes Jáni ◽  
Jon A Wolff

1992 ◽  
Vol 1 (1) ◽  
pp. 35-40 ◽  
Author(s):  
Dominic J.Wells ◽  
Kim E.Wells ◽  
Frank S.Walsh ◽  
Kay E.Davies ◽  
Geoffrey Goldspink ◽  
...  

Gene Therapy ◽  
2004 ◽  
Vol 11 (11) ◽  
pp. 901-908 ◽  
Author(s):  
K W Liang ◽  
M Nishikawa ◽  
F Liu ◽  
B Sun ◽  
Q Ye ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document